PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1465-542X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? ; volume:16 ; number:1 ; day:3 ; month:11 ; year:2014 ; pages:1-13 ; date:12.2014
Breast cancer research ; 16, Heft 1 (3.11.2014), 1-13, 12.2014

Schlagwort
Krebs
Onkologie

Urheber
Millican-Slater, R.
Beteiligte Personen und Organisationen
Dodwell, D.
Horgan, K.
McMahon, M.
Dall, B.
Sharma, N.
SpringerLink (Online service)

DOI
10.1186/bcr3735
URN
urn:nbn:de:1111-201702225599
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:55 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Millican-Slater, R.
  • Dodwell, D.
  • Horgan, K.
  • McMahon, M.
  • Dall, B.
  • Sharma, N.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer

HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients

HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers

Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer

Verbundene Objekte